MedTrace Logo

PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes

NCT03159559 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-05-18

No results posted yet for this study

Summary

This study is undertaken to determine if intravenous Lipo-PGE1 therapy would improve coronary microvascular perfusion in patients with ischemic heart disease by CMRI.

Conditions

  • Coronary Microvascular Perfusion in Patients With Ischemic Heart Disease

Interventions

DRUG

Lipo-PGE1

Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2017-12-31
Completion
2018-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03159559 on ClinicalTrials.gov